# Pediatric ADVAIR DISKUS Versus Oral Montelukast Chewable Tablets

> **NCT00328718** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 526 (—)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** montelukast (5mg QD)
- **DRUG:** Salmeterol/Fluticasone propionate Inhalation Powder (50/100mcg BID)

## Key facts

- **NCT ID:** NCT00328718
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-10
- **Primary completion:** 2007-04
- **Final completion:** 2007-04
- **Target enrollment:** 526 (—)
- **Last updated:** 2017-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00328718

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00328718, "Pediatric ADVAIR DISKUS Versus Oral Montelukast Chewable Tablets". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00328718. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*